Resultados globales: 2 registros encontrados en 0.01 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
9 p, 325.6 KB Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1) : a phase III, international, randomized, placebo-controlled study / Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan) ; Lenz, H. J. (Division of Medical Oncology, Norris Comprehensive Cancer Center, Los Angeles, USA) ; Lonardi, Sara (Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto - IRCCS, Padua) ; Falcone, Alfredo (Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy) ; Limón, M. L. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Saunders, M. (Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK) ; Sobrero, A. (Department of Medical Oncology, Azienda Ospedaliera San Martino, Genoa, Italy) ; Park, Y S. (Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea) ; Ferreiro, R. (Hospital Universitario Ramón y Cajal (Madrid)) ; Hong, Y S. (Department of Oncology, Asan Medical Center, Seoul, South Korea) ; Tomasek, J. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ; Taniguchi, H. (Aichi Cancer Center Hospital) ; Ciardiello, Fortunato (Oncologia Medica, Seconda Università deli Studi di Napoli, Naples, Italy) ; Stoehr, J. (Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany) ; Oum'Hamed, Z. (Boehringer Ingelheim France S.A.S, Reims, France) ; Vlassak, S. (SCS Boehringer Ingelheim Comm.V, Brussels, Belgium) ; Studeny, M. (Division of Medicine/Clinical Development Department, Boehringer Ingelheim, Vienna, Austria) ; Argiles, G.. (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. [...]
2018 - 10.1093/annonc/mdy241
Annals of oncology, Vol. 29 (july 2018) , p. 1955-1963  
2.
9 p, 1.1 MB Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab / Fuchs, Charles S. (Harvard Medical School) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Tomášek, Jiří (Masaryk University (Czech Republic)) ; Chau, Ian (Royal Marsden Hospital (Regne Unit)) ; Melichar, Bohuslav (Univerzity Palackeho a Fakultni nemocnice (Czech Republic)) ; Safran, Howard (Brown University Oncology Research Group (USA)) ; Tehfe, Mustapha A. (Centre Hospitalier de Montréal (Canada)) ; Filip, Dumitru (Spitalul Judetean de Urgenta (Romania)) ; Topuzov, Eldar (Northwest State Medical University na II Mechnikov) ; Schlittler, Luis (Hospital da Cida de Passo Fundo (Brasil)) ; Udrea, Anghel Adrian (Medisprof SRL (Romania)) ; Campbell, William (Hospital Herrera Llerandi (Guatemala)) ; Brincat, Stephen (Sir Anthony Mamo Oncology Centre (Malta)) ; Emig, Michael (Lilly Deutschland GmbH (Germany)) ; Melemed, Symantha A. (Lilly Corporate Center (USA)) ; Hozak, Rebecca R. (Lilly Corporate Center (USA)) ; Ferry, David (Lilly Corporate Center (USA)) ; Caldwell, C. William (Lilly Corporate Center (USA)) ; Ajani, Jaffer A. (The University of Texas MD Anderson Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. [...]
2016 - 10.1038/bjc.2016.293
British Journal of Cancer, Vol. 115, Issue 8 (October 2016) , p. 974-982  

Vea también: autores con nombres similares
1 Tomášek, Jiří
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.